VA Class: OP210
Chemical Name: (+)-7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
Molecular Formula: C19H21ClFN3O3•HCl
CAS Number: 405165-61-9
Antibacterial; 8-chloro fluoroquinolone.
Uses for Besifloxacin
Bacterial Ophthalmic Infections
Topical treatment of conjunctivitis caused by Aerococcus viridans, CDC coryneform group G, Corynebacterium pseudodiphtheriticum, C. striatum, Haemophilus influenzae, Moraxella catarrhalis, M. lacunata, Pseudomonas aeruginosa, Staphylococcus aureus, S. epidermidis, S. hominis, S. lugdunensis, S. warneri, Streptococcus mitis group, S. oralis, S. pneumoniae, or S. salivarius.
Many cases of mild, acute bacterial conjunctivitis resolve spontaneously without anti-infective therapy. Although topical ophthalmic anti-infectives may shorten time to resolution and reduce severity and risk of complications, avoid indiscriminate use of topical anti-infectives.
Treatment of acute bacterial conjunctivitis generally is empiric; use of a broad-spectrum topical ophthalmic antibacterial usually recommended. In vitro staining and/or cultures of conjunctival material may be indicated in diagnosis and management of recurrent, severe, or chronic purulent conjunctivitis or when acute conjunctivitis does not respond to initial empiric topical treatment.
Besifloxacin Dosage and Administration
Apply 0.6% ophthalmic suspension topically to the eye.
For topical ophthalmic use only; do not inject subconjunctivally and do not introduce directly into anterior chamber of the eye.
Wash hands prior to administration.
Invert the closed bottle containing besifloxacin ophthalmic suspension and shake once prior to each use.
Avoid contaminating applicator tip with material from eye, fingers, or other source.
Available as besifloxacin hydrochloride; dosage expressed in terms of besifloxacin.
Bacterial Ophthalmic Infections
Children ≥1 year of age: Instill 1 drop of 0.6% suspension in the affected eye(s) 3 times daily (give doses 4–12 hours apart) for 7 days.
Bacterial Ophthalmic Infections
Instill 1 drop of 0.6% suspension in the affected eye(s) 3 times daily (give doses 4–12 hours apart) for 7 days.
Cautions for Besifloxacin
Manufacturer states none known.
Although besifloxacin is not used systemically, consider that hypersensitivity reactions have been reported with systemic quinolones, even following a single dose.
Immediately discontinue at first sign of rash or hypersensitivity reaction.
For topical ophthalmic use only; not for injection into the eye.
Prolonged use may result in overgrowth of nonsusceptible organisms (e.g., fungi).
If superinfection occurs, discontinue besifloxacin ophthalmic suspension and institute appropriate therapy.
Whenever clinical judgment dictates, examine patient with the aid of magnification (e.g., slit lamp biomicroscopy) and, if appropriate, fluorescein staining.
Do not wear contact lenses during treatment with besifloxacin ophthalmic suspension or if any signs or symptoms of bacterial conjunctivitis are present.
Data not available regarding use of besifloxacin 0.6% ophthalmic suspension in pregnant women.
Although not measured in human milk, presumed to be distributed into human milk.
Use with caution in nursing women.
Safety and efficacy not established in children <1 year of age.
No overall differences in safety and efficacy relative to younger adults.
Common Adverse Effects
Interactions for Besifloxacin
No formal drug interaction studies using besifloxacin 0.6% ophthalmic suspension.
After topical application of besifloxacin 0.6% ophthalmic suspension to each eye 3 times daily for 16 doses, maximum plasma concentrations of the drug were <1.3 ng/mL.
Penetrates into conjunctiva and aqueous humor; maximum concentrations reported are 62.8 and 1.7 mcg/mL, respectively.
Average elimination half-life of systemically absorbed drug estimated to be 7 hours.
15–25°C. Protect from light.
Contains benzalkonium chloride as a preservative.
Actions and Spectrum
Like other fluoroquinolones, inhibits DNA synthesis in susceptible bacteria via inhibition of DNA topoisomerases (DNA gyrase, topoisomerase IV).
Spectrum of activity includes gram-positive aerobic bacteria and some gram-negative aerobic bacteria.
Active in vitro and in vivo in conjunctival infections against Aerococcus viridans, CDC coryneform group G, Corynebacterium pseudodiphtheriticum, C. striatum, Haemophilus. influenzae, Moraxella catarrhalis, M. lacunata, Pseudomonas aeruginosa, Staphylococcus aureus, S. epidermidis, S. hominis, S. lugdunensis, S. warneri, Streptococcus mitis group, S. oralis, S. pneumoniae, and S. salivarius.
Cross-resistance between besifloxacin and some other fluoroquinolones reported.
Advice to Patients
Advise patients to avoid contaminating applicator tip with material from the eye, fingers, or other source.
Instruct patients to wash their hands prior to administration of the ophthalmic suspension and to invert the closed bottle and shake once prior to each use.
Importance of completing the entire prescribed course of treatment, even if feeling better after a few days.
Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with besifloxacin or other antibacterials in the future.
Advise patients not to wear contact lenses during treatment with besifloxacin ophthalmic suspension or if any signs or symptoms of bacterial conjunctivitis are present.
Advise patients to immediately discontinue besifloxacin ophthalmic suspension and contact a clinician at first sign of rash or hypersensitivity reaction.
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
0.6% (of besifloxacin)
Bausch & Lomb
AHFS DI Essentials™. © Copyright 2022, Selected Revisions May 22, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
More about besifloxacin ophthalmic
- Side effects
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (2)
- En español
- Drug class: ophthalmic anti-infectives
- Other brands